Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).

John Allan, Erin Mulvey, Daniel Helbig, Nikita Malakhov, Zhengming Chen, Brittany Hobbie, Sarah Nazir, Jerrod White, Zahra Grant, Jane Matejka, Simone Morris, Liming Bao, Peter Martin, Richard Furman

Blood (2025) 146 (Supplement 1): 3886.

https://doi.org/10.1182/blood-2025-3886

Published: 2025

Journal Articles

Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH).

John Allan, Andrew Lipsky, Seema Bhat, Suchitra Sundaram, Lubing Wu, Jane Matejka, Brittany Hobbie, Nourhan Hamadi, Simone Morris, Zhengming Chen, Ivo Sah Bander, Madhu Ouseph, Jia Ruan, Amy Chadburn, Adam Kittai, Richard Furman

Blood (2025) 146 (Supplement 1): 3681.

https://doi.org/10.1182/blood-2025-3681

Published: 2025

Journal Articles

MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Jia Ruan, David A. Bond, Bijal D Shah, John N. Allan, Sarah C. Rutherford, Caitlin Gribbin, Zhengming Chen, Brittany Hobbie, Melinda Harbhajan, Tejasvi Sahni, Wayne Tam, Bhavneet Bhinder, Michael Sigouros, Giorgio Inghirami, Selina Chen-Kiang, Olivier Elemento, Kami J. Maddocks, John P. Leonard, Peter Martin

Blood (2024) 144 (Supplement 1): 746.

https://doi.org/10.1182/blood-2024-204495

Published: 2024

Journal Articles

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Jia Ruan, John P. Leonard, Gui Zhen Chen, Zhengming Chen, John N. Allan, Sarah C. Rutherford, Brittany Hobbie, Katie Greig, Amelyn Rodriguez, Wayne Tam, David A. Bond, Bijal D. Shah, Kami J. Maddocks, Bhavneet Binder, Giorgio Inghirami, Olivier Elemento, Selina Chen-Kiang, Peter Martin

Blood (2022) 140 (Supplement 1): 175–177.

https://doi.org/10.1182/blood-2022-158656

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).

Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH).

MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).

Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH).

MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only